Foldax is reinventing every aspect of the heart valve - from material to design to manufacturing - to develop surgical and transcatheter valves designed to last a lifetime addressing historical tradeoffs. The company is developing its Tria valve technology in partnership with Caltech and CSIRO, Australia's science agency.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/23/20 | $20,000,000 | Series D |
Angel Physicians Fund BioStar Capital Caltech Kairos Ventures MemorialCare Innovation Fund  Sayan Bioventures | undisclosed |
